日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial

Idecabtagene vicleucel 用于复发/难治性多发性骨髓瘤:一项 1 期试验的事后 18 个月随访

Yi Lin ,Noopur S Raje ,Jesús G Berdeja ,David S Siegel ,Sundar Jagannath ,Deepu Madduri ,Michaela Liedtke ,Jacalyn Rosenblatt ,Marcela V Maus ,Monica Massaro ,Fabio Petrocca ,Ashish Yeri ,Olivia Finney ,Andrea Caia ,Zhihong Yang ,Nathan Martin ,Timothy B Campbell ,Julie Rytlewski ,Jaymes Fuller ,Kristen Hege ,Nikhil C Munshi ,James N Kochenderfer